UCSF’s innovative, collaborative approach to patient care, research and education spans disciplines across the life sciences, making it a world leader in scientific discovery and its translation to improving health.
Molly studied Neuroscience and Psychology at the University of California, Los Angeles. She then completed her PhD degree with Professor Peter Juo at Tufts University, where she investigated the regulation of the AMPA-type glutamate receptor by its deubiquitinating enzyme USP-46 in C. elegans. She identified two novel mechanisms by which USP-46 is stabilized and activated by two WD40-repeat proteins, WDR-48 and WDR-20, to promote AMPAR abundance and recycling to the neuronal surface. In the Kao lab, Molly will continue her research in protein homeostasis and degradation in C.
The Clelland laboratory aims to develop cures for dementia and related neurodegenerative diseases. She is focused on single-gene (monogenic) causes of frontotemporal dementia and amyotrophic lateral sclerosis, such as mutations in the C9orf72 gene. She and her team develop CRISPR gene editing approaches in relevant cell types derived from human iPSCs and are working to develop better cell model systems of disease.
Aimee Kao, MD, PhD, is a Professor of Neurology at the University of California, San Francisco and the John Douglas French Foundation Endowed Professor. She leads an NIH-supported Tau Center Without Walls and directs the UCSF Tau Consortium Human Fibroblast Bank. Dr.
